Detail akcie Biogen Idec online

Business Summary: Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Biogen Inc revenues decreased 2% to $9.68B. Net income increased 41% to $1.63B. Revenues reflect Rest of World-Other revenues segment decrease of 27% to $652.6M, Rest of World segment decrease of 3% to $3.98B. Net income reflects Biopharmaceutical segment income increase of 40% to $2.25B. Basic Earnings per Share excluding Extraordinary Items increased from $8.02 to $11.21.